EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025)

Nafeesa Naeem, Ehsan Ullah Mughal iD, Amina Sadiq, Gehan Ahmed Othman, Bushra Shakoor

Archiv der Pharmazie · 2025-07 · 358 (7)

DOI: 10.1002/ardp.70059 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, online erschienen am 29.07.2025. Verfasst von Nafeesa Naeem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Gujrat, Gujrat, Pakistan. Hauptthemen laut MEDLINE: Triazoles, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 113 Literaturangaben. Gefördert von: This work was funded by the King Khalid University (RGP2/370/46)., King Khalid University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 1,2,4‐triazole scaffold has emerged as a privileged heterocyclic core in the development of anticancer agents due to its unique physicochemical properties, bioavailability, and diverse biological activities. Over the past few years, significant advancements have been made in the design and structural optimization of 1,2,4‐triazole‐based anticancer compounds, with a strong focus on their structure–activity relationships (SARs). This review provides a comprehensive overview of the latest developments (2022–2025) in 1,2,4‐triazole‐containing anticancer agents, emphasizing their mechanisms of action, molecular targets, and therapeutic potential. The discussion encompasses the various modifications introduced into the 1,2,4‐triazole core, exploring their impact on anticancer efficacy, selectivity, and pharmacokinetic properties. In particular, recent studies have highlighted the ability of these derivatives to inhibit key cancer‐related enzymes (such as kinases, carbonic anhydrases, and topoisomerases), interfere with DNA interactions, and modulate apoptotic and autophagic pathways. This review also presents emerging SAR trends, highlighting key functional group modifications that enhance anticancer potency while minimizing off‐target effects. Furthermore, recent in vivo studies and clinical evaluations of promising 1,2,4‐triazole derivatives are discussed to assess their translational potential. Lastly, we outline future research directions and challenges in the development of next‐generation triazole‐based anticancer agents, aiming to bridge the gap between rational drug design and clinical application. This comprehensive analysis underscores the critical role of the 1,2,4‐triazole pharmacophore in anticancer drug discovery and provides valuable insights for the design of more potent and selective anticancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazolesAntineoplastic AgentsNeoplasmsHumansStructure-Activity RelationshipAnimalsMolecular StructureDrug Design

Stichwörter der Autor:innen

124‐triazoleanticancerhybrid heterocyclic compoundsstructure–activity relationship

Substanzen

TriazolesAntineoplastic Agents1,2,4-triazole

Autor:innen und Institutionen

  • Department of Chemistry, University of Gujrat, Gujrat, Pakistan.
  • Department of Chemistry, Govt. College Women University, Sialkot, Pakistan.
  • Biology Department, College of Science, King Khalid University, Abha, Saudi Arabia.
  • Synthetic & Natural Product Discovery Lab., Department of Chemistry, Government College Women University Faisalabad, Pakistan.

ORCID-Profile: Ehsan Ullah Mughal

Förderung

  • This work was funded by the King Khalid University (RGP2/370/46).
  • King Khalid University

Zitieren

APA

Naeem, N., Mughal, E. U., Sadiq, A., Othman, G. A., & Shakoor, B. (2025). Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025). Archiv der Pharmazie, 358(7). https://doi.org/10.1002/ardp.70059

Vancouver

Naeem N, Mughal EU, Sadiq A, Othman GA, Shakoor B. Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025). Archiv der Pharmazie. 2025;358(7). doi:10.1002/ardp.70059

BibTeX
@article{Naeem2025,
  author = {Naeem, Nafeesa and Mughal, Ehsan Ullah and Sadiq, Amina and Othman, Gehan Ahmed and Shakoor, Bushra},
  title = {Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025)},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {7},
  doi = {10.1002/ardp.70059}
}
Kostenlos starten →